Entrectinib as first-line vs. second-line therapy in ROS1 fusion-positive non-small cell lung cancer: a cost-effectiveness analysis
@article{TLCR85530,
author = {Gengwei Huo and Ying Song and Xiongwen Chen and Peng Chen},
title = {Entrectinib as first-line vs. second-line therapy in ROS1 fusion-positive non-small cell lung cancer: a cost-effectiveness analysis},
journal = {Translational Lung Cancer Research},
volume = {13},
number = {4},
year = {2024},
keywords = {},
abstract = {},
issn = {2226-4477}, url = {https://tlcr.amegroups.org/article/view/85530}
}